通脉养心丸减轻阿霉素致小鼠急性心脏毒性的作用研究

Effect of Tongmai Yangxin Pills on alleviating acute cardiotoxicity induced by doxorubicin in mice

[目的]探究通脉养心丸对阿霉素致急性心脏毒性小鼠的保护作用。[方法]通过对小鼠单次腹腔注射阿霉素20 mg/kg,建立阿霉素致急性心脏毒性小鼠模型。对比空白对照组、阿霉素组、阿霉素+通脉养心丸低、中、高剂量组小鼠给予阿霉素后第3天、第12天的一般情况,观察心脏超声、血清心肌酶(CK)、乳酸脱氢酶(LDH)、肌钙蛋白I(cTn-I)和超氧化物歧化酶(SOD)含量以及组织病理学变化。[结果]与空白对照组相比,阿霉素组小鼠体质量降低,死亡率升高,左室射血分数(EF),左室短轴缩短率(FS)均降低,血清CK、LDH值和血清cTn-I含量升高,血清SOD含量降低,组织病理学结果显示阿霉素组小鼠心肌细胞排列紊乱,肌原纤维丢失,核周空泡化和细胞质空泡化。与阿霉素组相比,通脉养心丸各剂量组小鼠死亡率降低,生存时间延长,EF、FS值升高,血清CK、LDH值和血清cTn-I含量降低,血清SOD含量升高,组织病理学的结果显示心肌损伤程度逐渐减轻,心肌细胞较为完整,心肌组织明显改善。[结论]通脉养心丸能够减轻阿霉素诱导的急性心脏毒性。

[Objective]To explore the protective effect of Tongmai Yangxin Pills on doxorubicin induced acute cardiotoxicity mice.[Methods]Acute cardiotoxicity mice model induced by doxorubicin was established by single intraperitoneal injection of 20 mg/kg doxorubicin.The general conditions of mice DOX in blank control group,doxorubicin group,doxorubicin+Tongmai Yangxin Pill low-dose,medium-dose and high-dose groups were compared on day 3,day 7 and day 14 after DOX.Cardiac ultrasound,serum contents of CK,LDH,cTn-I and SOD and histopathological changes were observed.[Results]Compared with the blank control group,doxorubicin group mice weight loss,higher mortality,EF,FS value are reduced,serum CK,LDH values and serum cTn-I content is higher,lower serum SOD content,histopathological results show that the disordered arrangement of doxorubicin group mice cardiomyocytes,myofibril lost week of nuclear vacuoles and cytoplasmic vacuoles.Compared with doxoruxin group,the mortality and survival time of mice in Tongmai Yangxin Pills groups were decreased,the EF and FS values were increased,the serum CK and LDH values and the serum cTn-I content were decreased,and the serum SOD content was increased.The histopathological results showed that the degree of myocardial injury was gradually alleviated,the myocardial cells were more intact,and the myocardial tissue was significantly improved.[Conclusion]Tongmai Yangxin Pills can alleviate acute cardiotoxicity induced by doxorubicin.